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Aim To determine the relationship between scores on 
five factors of the Positive and Negative Syndrome Scale 
(PANSS) and Calgary Depression scale for Schizophrenia 
(CDSS) and scores on the InterSePT Scale for Suicidal Think-
ing (ISST) in patients with acute schizophrenia.
Methods Data were collected on sociodemographic 
and clinical characteristics of 180 drug-treated in-patients 
with acute schizophrenia. Their symptoms were assessed 
with PANSS, CDSS, and ISST and correlations between the 
scores were calculated. Statistically significant correlations 
were included in the logistic regression analysis to identify 
predictors of suicidal risk.
Results CDSS (P < 0.001) score and negative (P < 0.001), 
disorganized (P = 0.041), emotional (P < 0.001), and total 
score on PANSS (P < 0.001) showed a significant positive 
correlation with ISST. Stepwise logistic regression analysis 
revealed that CDSS scores (odds ratio [OR] 5.18; confidence 
interval [CI] 1.58-16.95), and disorganized (0.90; 0.81-0.99) 
and emotional (1.15; 1.01-1.30) factors of PANSS were pre-
dictors of suicidal risk.
Conclusion Our results suggested a considerable asso-
ciation between depressive syndrome as assessed by the 
PANSS emotional factor and CDSS score and suicidal risk in 
patients with acute schizophrenia.
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Suicide is a major cause of death in patients with schizo-
phrenia. The estimated lifetime rate for suicide in schizo-
phrenia is about 5% (1). Many studies explored the re-
lationship between psychiatric symptomatology and 
suicide in patients with schizophrenia and obtained con-
tradictory results. However, most of the studies showed 
a strong association between suicide and depressive 
symptoms, especially in the acute phase of the illness 
(2-9). Among hospitalized patients, suicidal risk peaks 
shortly after admission and shortly after discharge from 
hospital (10). The association between positive and nega-
tive symptoms and suicidal risk is less clear. A large meta-
analysis showed inconsistent results on the role of pos-
itive and negative symptoms in suicidal risk in patients 
with schizophrenia (11). Schizophrenia has been con-
sidered a clinically heterogeneous entity and – accord-
ing to contemporary concepts – a syndrome with di-
verse symptoms (12). One of the major attempts to make 
this heterogeneous entity more structured was Positive 
and Negative Syndrome Scale (PANSS), which consists of 
three symptom clusters: positive, negative, and general 
psychopathology (13). It is still the most frequently used 
instrument for rating schizophrenia symptoms, which are 
currently clustered into five factors that are more appro-
priate for description of relevant heuristic clinical dimen-
sions called “positive,” “negative,” “emotional,” “excitement,” 
and “disorganization” (14-23). Although a few models of 
universal item distribution have been proposed (24-27), 
the consensus is still lacking.
To help distinguish schizophrenia symptoms from de-
pression and suicidal behavior, new questionnaires were 
developed. Calgary Depression Scale for Schizophrenia 
(CDSS) (28) was specifically developed to assess the level 
of depression in schizophrenia and found to be superior 
to other depression-rating scales (29,30). Lindenmayer et 
al (31) derived the InterSePT Scale for Suicidal Thinking 
(ISST) from the Scale for Suicide Ideation (32) by adjust-
ing the scale for measuring the suicidal risk in depressed 
population and assessing current suicidal ideation in pa-
tients with schizophrenia and schizoaffective disorder 
(33-35).
The phenomenon of suicidal behavior still remains unex-
plored. Besides psychological, recent studies are focused 
on biological factors (36,37). Our study was designed to 
determine the relationship between scores on ISST, CDSS, 
and symptom clusters derived from five-factor PANSS anal-




This cross-sectional study included patients recruited from 
the Department for Diagnostics and Intensive Care and the 
Department for Treatment and Rehabilitation, Psychiatric 
University Hospital Vrapče between January 2007 and June 
2009. Patients of both sexes, aged over 18 years, with intel-
lectual and legal capacity to participate in the study, who 
were diagnosed with schizophrenia according to DSM-IV 
criteria (38) by two independent evaluators were eligible 
for the study. Exclusion criteria were treatment with antide-
pressants and any co-morbid psychiatric or somatic disor-
der that might influence clinical presentation, ie, alcohol or 
substance abuse, psychoorganic syndrome, neurological 
trauma or disease, or severe somatic disease.
The study sample consisted of 180 drug-treated inpa-
tients with a mean (range) PANSS score of 98.0 (86.3-109.0), 
which is equivalent of “markedly ill” according to the Clini-
cal Global Impression Scale (39) (Table 1).
Participation in the study was voluntary. All patients gave 
informed consent. The study was approved by the Ethics 
Committees of the Psychiatric University Hospital Vrapče 
and the Osijek University School of Medicine.
Clinical assessment
PANSS was used for evaluation of schizophrenia symp-
toms (13). Factors were calculated using five-factor model 
of PANSS by Van der Gaag et al (24,25) according to the 
formula:
1) Positive: delusions (P1) + hallucinatory behavior (P3) + 
unusual thought content (G9) + suspiciousness/persecu-
tion (P6) + grandiosity (P5) + somatic concerns (G1) + lack 
of judgment and insight (G12) + active social avoidance 
(G16) – difficulty in abstract thinking (N5)
2) Negative: lack of spontaneity and conversation flow (N6) 
+ blunted affect (N1) + emotional withdrawal (N2) + pas-
sive/apathetic social withdrawal (N4) + motor retardation 
(G7) + poor rapport (N3) + active social avoidance (G16) + 
uncooperativeness (G8) + disturbance of volition (G13) – 
conceptual disorganization (P2)
3) Disorganization: stereotyped thinking (N7) + poor 
attention (G11) + disorientation (G10) + conceptu-
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al disorganization (P2) + difficulty in abstract thinking (N5) 
+ mannerisms/posturing (G5) + lack of judgment and in-
sight (G12) + disturbance of volition (G13) + preoccupa-
tion (G15) + unusual thought content (G9)
4) Excitement: poor impulse control (G14) + excitement 
(P4) + hostility (P7) + uncooperativeness (G8) + grandios-
ity (P5) + poor rapport (N3) + tension (G4) + active social 
avoidance (G16)
5) Emotional: anxiety (G2) + depression (G6) + guilt feel-
ings (G3) + tension (G4) + suspiciousness/persecution (P6) 
+ somatic concerns (G1) + preoccupation (G15) + active 
social avoidance (G16).
CDSS was used to evaluate depressive symptoms. To dis-
tinguish patients with depression from those without 
depression, the value of 7 was used as a cut-off point. 
The same value was used by Addington et al to distin-
guish between depressive patients and patients with-
out depression (40), by Bressan et al to distinguish be-
tween patients with major depression and patients with 
moderate or without depression (41), and Müller et al to 
distinguish between patients with moderate and severe 
depression and those with mild depression or without 
depression (42).
ISST was used for the assessment of current suicidal ide-
ation; the cut-off value of 6 was used to distinguish be-
tween patients with and without suicidal risk (43).
Median time from admission to psychometric evaluation 
was 4.0 days (25% quartile: 3.0 days, 75% quartile: 4.0 days). 
PANSS, CDSS, and ISST measurements were performed on 
the same day by three independent psychiatrists blinded 
to the scores on other scales.
statistical analysis
Normality of data distribution was assessed with Smirnov-
Kolmogorov test. Since only PANSS showed a normal dis-
tribution, nonparametric tests were used in the analysis. 
Differences between male and female participants were 
analyzed with χ2 test (categorical values) and Mann-Whit-
ney U test (quantitative values). Spearman correlation co-
efficients were calculated between ISST score and five 
PANSS factors and CDSS score. Logistic regression analysis 
was used to test the relationship between ISST scores (di-
chotomized as <6 and ≥6) as a dependent variable and 
sample variables (sex, suicide in family, schizophrenia in 
family, previous attempt of suicide), PANSS scores (nega-
tive, disorganization, emotional), and CDSS score (dichoto-
mized as <7 and ≥7) as independent variables. A stepwise 
tABle 1. Demographic and clinical characteristics of patients with acute schizophrenia*
Variables Men (n = 95) Women (n = 85) total (n = 180) P
Age (years, median and interquartile range) 29.0 (25.0-39.0) 36.0 (27.0-47.0) 32.0 (25.0-43.5)  0.002‡
Duration of illness (years, median and interquartile range)   2.0 (0.5-8.0)  3.0 (1.0-9.3)  2.9 (0.8-8.5)  0.272‡
Age of onset (years, median and interquartile range)  25.0 (21.0-29.9) 29.8 (23.3-38.2) 27.8 (21.9-33.3) <0.001‡
No. of previous hospitalizations (median and interquartile range)   1.0 (0.0-3.0)  2.0 (0.0-4.0)  1.5 (0.0-4.0)  0.326‡
No. of previous suicide attempts (median and interquartile range)   0.0 (0.0-1.0)  0.0 (0.0-1.0)  0.0 (0.0-1.0)  0.405‡
Family history of (No., %):†
schizophrenia  33 (34.7) 19 (22.4) 52.0 (28.9)  0.096§
depression   5 (5.3)  6 (7.1) 11.0 (6.1)  0.849§
suicide   9 (9.5) 14 (16.5) 23.0 (12.8)  0.238§
PANss
total score 102.0 (90.0-111.0) 93.0 (84.0-105.0) 98.0 (86.5-109.0)  0.001‡
positive (median and interquartile range)  27.0 (22.0-30.0) 25.0 (21.0-28.0) 26.0 (21.5-29.0)  0.012‡
negative (median and interquartile range)  26.0 (22.0-30.0) 24.0 (21.0-29.0) 26.0 (21.0-29.0)  0.146‡
disorganized (median and interquartile range)  33.0 (28.0-38.0) 30.0 (27.0-35.0) 31.0 (27.5-36.0)  0.003‡
excitement (median and interquartile range)  27.0 (24.0-31.0) 24.0 (21.0-29.0) 26.0 (22.0-30.00)  0.002‡
emotional (median and interquartile range)  28.0 (25.0-31.0) 27.0 (24.0-30.0) 27.0 (24.0-31.0)  0.113‡
CDss total score (median and interquartile range)   6.0 (0.0-12.0)  5.0 (2.0-11.0)  5.0 (0.0-12.0)  0.892‡
Isst total score (median and interquartile range)   1.0 (0.0-6.0)  0.0 (0.0-2.0)  0.0 (0.0-4.0)  0.004‡
*PANss – Positive and Negative syndrome scale; CDss – Calgary Depression scale for schizophrenia; Isst – Intersept scale for suicidal thinking.
†some patients had multiple heredity.
‡Mann-Whitney test.
§χ2 test.
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model was used. Sample variables were entered in the first 
block and scale scores in the second. P-values <0.05 were 
considered statistically significant. The analyses were per-
formed using the SPSS for Windows, release 17 (SPSS Inc., 
Chicago, IL, USA).
Results
Cronbach alpha coefficients showed high internal 
consistency for CDSS and ISST scales (αCDSS = 0.92 
and αISST = 0.96). Internal consistencies of PANSS fac-
tors formed according to van der Gaag (24,25) were 
somewhat lower, but still high or within the accept-
able range (αpositive = 0.73; αnegative = 0.83; αdisorganization = 0.81; 
αexcitement = 0.70; αemotional = 0.64).
Men had higher ISST scores, PANSS total score, and posi-
tive, disorganized, and excitement PANSS factor scores 
than women (Table 1). Patients with heredity of suicide 
had higher ISST scores [C = 6.0 (Q1-Q3) = 1.0-11.0 vs 0.0 
(0.0-3.0); P = 0.003; Mann-Whitney U test], as well as pa-
tients with heredity of schizophrenia [1.0 (0.0-6.5 vs 0.0 
(0.0-3.0); P = 0.039]. Heredity of depression was not asso-
ciated with higher ISST score. Patients with more suicide 
attempts had higher ISST scores (Table 2). CDSS, PANSS to-
tal score, and negative, disorganized, and emotional PANSS 
factor scores positively correlated with ISST scores (Table 
2). CDSS also showed a strong correlation with emotional 
PANSS factor (rho = 0.508).
Of 180 patients, 79 (43.9%) had CDSS score equal or higher 
than 7, and 34 (43.0%) had ISST score equal or higher than 6.
We performed a stepwise logistic regression analysis using 
all variables with moderate or high association with ISST as 
dependent variables. We entered patients’ variables in the 
first block and added CDSS and PANSS factors correlating 
with ISST in the second block. Variables in the first block 
explained 61% of variance in the dependent variable, with 
previous attempt of suicide, sex (men had greater odds for 
higher ISST), and suicide in family as significant predictors. 
Adding PANSS and CDSS scale scores in the second block 
explained additional 10% of variance in the criterion. Previ-
ous attempt of suicide, male sex, and suicide in family re-
mained significant with PANSS disorganized factor score, 
PANSS emotional factor score, and CDSS score as addition-
al predictors (Table 3).
DIsCussION
Our study showed that the PANSS total score, disorganized, 
negative, and emotional PANSS factor scores, and CDSS 
were positively correlated with suicidal risk. Among PANSS 
factors, emotional factor showed the strongest correlation. 
The CDSS showed the strongest correlation of all assessed 
variables, which was also found by Lindermayer et al (30). 
A significant positive correlation was also found between 
suicidal risk and male sex, heredity of schizophrenia, hered-
ity of suicide, and number of previous suicide attempts.
tABle 2. Correlation between Isst scores and patient vari-
ables, CDss and PANss scores*
Variable Correlation with Isst P†
Age 0.019 0.803
Sex -0.217 0.003
Heredity of depression 0.097 0.194
Heredity of schizophrenia 0.154 0.039
Heredity of suicide 0.221 0.003
Duration of illness 0.127 0.088
Age of onset -0.058 0.438
No. of previous hospitalizations 0.040 0.592








*Isst – Intersept scale for suicidal thinking; CDss – Calgary Depres-
sion scale for schizophrenia; PANss – Positive and Negative syndrome 
scale.
†spearman’s rho.
tABle 3. logistic regression model for Intersept scale for 







Block 1 sex  0.18 (0.11-0.29)† 0.61
heredity of schizophrenia  1.00 (0.42-2.43)
heredity of suicide  4.31 (1.42-13.10)†
previous suicide attempt 11.84 (4.82-29.10)†
Block 2 sex  0.15 (0.06-0.39)† 0.71
heredity of schizophrenia  0.96 (0.35-2.65)
heredity of suicide  3.95 (1.11-14.06)†
previous attempt 10.92 (3.95-30.14)†
CDSS (<7 / ≥7)  5.18 (1.58-16.95)†
PANSS negative  0.96 (0.85-1.08)
PANSS disorganized  0.90 (0.81-0.99)†
PANSS emotional  1.15 (1.01-1.30)†
*CDss – Calgary Depression scale for schizophrenia; PANss – Positive 
and Negative syndrome scale.
†significant predictor (P < 0.05).
BRAIN AND MENTAL HEALTH 440 Croat Med J. 2013;54:436-43
www.cmj.hr
The logistic regression model revealed that CDSS and 
emotional and disorganized PANSS factors were predictors 
of suicidal risk. Among patients’ variables, male sex, hered-
ity of suicide, and previous suicidal attempts were predic-
tors of suicidal risk. Similar findings were shown in previous 
studies (7,44-50).
The study was centered on associations between clinical 
features of acute schizophrenia and suicidal risk, which 
were assessed in a distinct constellation of psychometric 
tools and their interpretations. Contrary to other clusters of 
symptoms (with the exception of disorganized), the study 
proved depressive syndrome as a stable and strong predic-
tor of suicidal risk, regardless of the related variable. Both 
CDSS and emotional factor, which is considered the PANSS 
equivalent of approximation of depressive syndrome (51), 
were predictors. Predictive value of disorganized cluster 
should be explored in further studies.
Results should be interpreted in the context of five-fac-
tor model. Although several universal models have been 
proposed, there is still no consensus. We chose the model 
by van der Gaag et al, which, unlike other item-restrictive 
universal models (26,27), uses multiple and negative item 
loadings and, therefore, is item-redundant. It is possible 
that other models would show different results with the 
same data. Furthermore, because causal or inductive as-
sociations between schizophrenia symptoms and PANSS 
items are still unknown, the question remains whether 
the selection of other items, not related to any of the sug-
gested five-factor models, would show stronger associa-
tions. Especially interesting is the emotional factor, which 
showed the strongest correlation with suicidal risk. In Van 
der Gaag’s model, it consists of eight items (G2 + G6 + 
G3 + G4 + P6 + G1 + G15 + G16) and is highly different 
from equivalent factors of other models. For instance, it 
has twice as many items as emotional factor in the model 
by El Yazaji et al (G1 + G2 + G3 + G6) and has also shown 
a significant correlation with CDSS (51). One of PANSS dis-
advantages is multidimensionality – item scores and as-
sociated description of each item often describe different 
psychopathological constructs. Given that depression 
is one of the PANSS items, PANSS measures otherwise 
poorly differentiated depressive syndrome consisting of 
mood, vegetative, and cognitive symptoms. Additional-
ly, there is no item that explicitly investigates suicidality. 
We found a positive correlation between negative symp-
toms and suicidal risk, contrary to some previous stud-
ies (7,52,53). This finding could be explained by the 
overlap between negative and depressive symp-
toms and difficulties in their differentiation with respect 
to poor conceptualization, which is the result of unknown 
nosology of each symptom and syndrome. Recognition 
of depressive symptoms should be an integral part of 
routine clinical evaluation of patients with schizophre-
nia. Some aspects of schizophrenia may mask depression 
symptoms and complicate their treatment. Since clini-
cians are usually focused on positive and negative symp-
toms of illness, depression often remains unrecognized 
and underestimated. Patients with predominantly posi-
tive symptoms, who respond well to antipsychotic thera-
py, are at the greatest risk of unrecognized depression. As 
negative symptoms are less correlated with increased risk 
of suicidal behavior, their overlap with depressive symp-
toms and unrecognized depression might lead to inad-
equate treatment and increased suicidal risk.
The limitation of our study was a relatively small study sam-
ple with a considerable proportion of depressive patients. 
Seventy-nine patients were depressive, 43% of whom were 
at increased suicidal risk. This high percentage of depres-
sive patients in our sample could be explained with a high 
proportion of patients with first episode of schizophrenia, 
who are known to have a higher incidence of depressive 
symptoms than patients with multiple episodes of schizo-
phrenia (54). A relatively small number of previous suicidal 
attempts was also the result of relatively high proportion of 
patients with first episode of schizophrenia, which might 
weaken the validity of related correlation.
In our study, antidepressant treatment was one of the 
exclusion criteria. Although antipsychotic genesis of de-
pressive syndrome in schizophrenia is often mentioned, 
Krakowski et al (55) found that antipsychotics might have 
two-sided effect on depressive symptoms, while Siris et 
al (56) did not find any difference in the prevalence of 
depression in schizophrenia between patients who were 
and those who were not treated with antipsychotics. A 
study with drug-untreated patients might show different 
results.
In conclusion, in their everyday practice, clinicians are often 
focused on the most prominent aspect of clinical features 
in patients with acute schizophrenia, ie, on productive 
and disorganized symptoms, which may mask depressive 
symptoms. These symptoms were shown to be strongest 
predictors of suicidal risk and, therefore, should be careful-
ly assessed. The same caution is required in assessing the 
overall patient history, clinical presentation, and heteroan-
amnestic data.
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